Anebulo Pharmaceuticals Price Target Cut to $3 Amidst Positive Outlook

Anebulo Pharmaceuticals (ANEB) saw its price target reduced from $6 to $3 by Maxim, but retains a Buy rating. The firm is optimistic about Anebulo's future in addressing severe cannabis toxicity. Based on 2 analysts' one-year price targets, the average target price is $5.50, indicating an upside of 461.22% from the current price of $0.98. The average brokerage recommendation is 2.0, indicating an "Outperform" status.

Anebulo Pharmaceuticals (ANEB) has seen its price target reduced from $6 to $3 by Maxim, but the firm maintains a Buy rating and is optimistic about the company's future in addressing severe cannabis toxicity. Based on the one-year price targets from two analysts, the average target price is $5.50, indicating an upside of 461.22% from the current price of $0.98. The average brokerage recommendation is 2.0, indicating an "Outperform" status.

Anebulo Pharmaceuticals, a clinical-stage biotechnology company, is developing ANEB-001, a novel treatment for acute cannabinoid intoxication. The company has been making significant strides in advancing its lead product candidate, intravenous selonabant, designed to treat acute cannabis-induced toxic effects, particularly in children.

Financial Performance

In the third quarter of fiscal year 2025, Anebulo reported operating expenses of $1.9 million, a net loss of $1.7 million or $(0.04) per share, and cash and cash equivalents of $13.3 million as of March 31, 2025. The company has access to an additional $3 million through a Loan Agreement [1].

Clinical Progress

The company plans to initiate a Phase 1 single ascending dose (SAD) study in healthy adult volunteers aged 18-25 years in Q3 2025. This study will evaluate the safety and pharmacokinetics of intravenous selonabant. The FDA has acknowledged the unmet need for treating cannabis toxicity in children, and Anebulo is addressing this need through its ongoing development efforts [1].

Analyst Sentiment

Maxim's reduction in the price target to $3 reflects the company's current valuation, but the firm's optimism about Anebulo's future is evident in the maintained Buy rating. The average one-year price target of $5.50 suggests significant potential for growth, with an average brokerage recommendation indicating an "Outperform" status.

Conclusion

Anebulo Pharmaceuticals is well-positioned to address a critical unmet medical need with its intravenous selonabant formulation. While the company faces financial challenges, its progress in clinical development and the growing unmet need for a cannabis antidote, particularly for children, provide a strong foundation for future growth. Investors should closely monitor Anebulo's clinical trial results and regulatory updates.

References

[1] https://www.stocktitan.net/news/ANEB/anebulo-pharmaceuticals-reports-third-quarter-fiscal-year-2025-59glt028oiz2.html